Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study.

NCT00334412 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00334412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00334412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AmBisome® in Combination With Caspofungin Versus AmBisome® High Dose Regimen for the Treatment of Invasive Aspergillosis in Immunocompromized Patients: Randomized Pilot Study.
Lead sponsor
Gilead Sciences
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2004
Completion date
May 31, 2006
Enrollment
30
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis